April 24, 2012 – Last week, Health Canada announced that it was requiring new bladder cancer warnings to be added to labels of Takeda’s controversial diabetes drug Actos (generic: pioglitazone). The move came following a safety review of the drug that was launched last year, when the U.S. Food & Drug Administration (FDA) required similar warnings for Actos in this country. Signs and symptoms of Actos-induced bladder cancer may include blood in the urine, pain during urination, and frequent urinary tract infections.
Actos Bladder Cancer Lawsuit Update April 8, 2014: In the first U.S. trial of its kind, Takeda Pharmaceuticals and Eli Lilly were ordered to pay a total of $9 billion in punitive damages after a jury agreed that the companies failed to warn the public and medical communities about the bladder cancer risk associated with their controversial type 2 diabetes drug Actos (pioglitazone). The lawsuit claimed that Takeda and Lilly downplayed or ignored concerns about Actos’ link to bladder cancer, and mislead health authorities in order to protect profits. Click here to learn more.
Free Actos Bladder Cancer Lawsuit Evaluation: If you or a loved one has been diagnosed with bladder cancer after taking Actos, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer of Actos and we can help.
What’s the problem?
According to the results of Health Canada’s safety review, the risk of bladder cancer from Actos appears to be dose-specific, meaning that the potential for the disease is significantly increased in users who took the drug at the highest dose over a prolonged period of time.
The Actos bladder cancer warnings will be added to all drug labels sold throughout Canadian provinces and territories. Health Canada has recommended that Actos not be prescribed to individuals with active bladder cancer, a previous history of bladder cancer, or problems with blood or blood clots in their urine.
First approved by the FDA in July 1999, Actos is a once-a-day oral prescription medication designed to increase the body’s sensitivity to insulin. Actos has been widely prescribed in recent years, and is Takeda’s best-selling medication, generating a mind-boggling $4.3 billion in sales last year alone.
Here at home in the United States, federal health regulators began investigating the link between Actos and bladder cancer in September 2010, after interim data from an ongoing decade-long study found that users face an increased risk of the disease the longer they undergo treatment with the drug.
Actos was recalled in both France and Germany in 2011 as a result of the risk of bladder cancer, and the drug has faced increased restrictions throughout the rest of the European Union (EU) over the past several years.
The new developments come as a multitude of Actos bladder cancer lawsuits continue to be filed in courthouses around the country, with many more cases expected in the near future. All of the suits involve similar claims that Takeda failed to provide adequate warnings to the public about the risks of taking Actos, and that the company actively attempted to conceal the risk from consumers and the medical community.
All Actos lawsuits filed on the federal level have been consolidated as part of a multidistrict litigation (MDL), which is currently centralized in the U.S. District Court for the Western District of Louisiana.
Do You Have an Actos Bladder Cancer Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Actos lawsuits. We are handling individual litigation nationwide and currently accepting new bladder cancer cases in all 50 states.
Free Actos Bladder Cancer Lawsuit Evaluation: If you or a loved one has been diagnosed with bladder cancer after taking Actos, you should contact our law firm immediately. You may be entitled to compensation by filing an Actos bladder cancer suit and we can help.